Showing results (181-190 of 656) with videos related to

Sort By:
Pageof 66
The Lancet. Microbe|May 24, 2025
Population-level impact of mass drug administration against schistosomiasis with anthelmintic drugs targeting juvenile schistosomes: a modelling studyBenjamin J Singer, Mireille Gomes, Jean T Coulibaly, et al.
The Lancet. Microbe|May 11, 2022
Clinical relevance and plasmid dynamics of mcr-1-positive Escherichia coli in China: a multicentre case-control and molecular epidemiological studyYan Jiang, Ying Zhang, Jun Lu, et al.
The Lancet. Microbe|May 11, 2022
Epidemiological and molecular investigations of a point-source outbreak of Dracunculus medinensis infecting humans and dogs in Chad: a cross-sectional studySarah Anne J Guagliardo, Elizabeth Thiele, Karmen Unterwegner, et al.
The Lancet. Microbe|May 11, 2022
The bacteriology of pleural infection (TORPIDS): an exploratory metagenomics analysis through next generation sequencingNikolaos I Kanellakis, John M Wrightson, Stephen Gerry, et al.
The Lancet. Microbe|May 11, 2022
Prevalence and subtyping of biofilms present in bronchoalveolar lavage from children with protracted bacterial bronchitis or non-cystic fibrosis bronchiectasis: a cross-sectional studyRobyn L Marsh, Michael J Binks, Heidi C Smith-Vaughan, et al.
The Lancet. Microbe|May 11, 2022
Resistome and virulome accretion in an NDM-1-producing ST147 sublineage of Klebsiella pneumoniae associated with an outbreak in Tuscany, Italy: a genotypic and phenotypic characterisationVincenzo Di Pilato, Lucia Henrici De Angelis, Noemi Aiezza, et al.
The Lancet. Microbe|May 11, 2022
Identification of immunodominant Bartonella bacilliformis proteins: a combined in-silico and serology approachAlexander A Dichter, Tilman G Schultze, Anne Wenigmann, et al.
The Lancet. Microbe|May 11, 2022
Immune-mediated attenuation of influenza illness after infection: opportunities and challengesManish M Patel, Ian A York, Arnold S Monto, et al.
The Lancet. Microbe|May 11, 2022
Virus persistence after recovery from acute Lassa fever in Nigeria: a 2-year interim analysis of a prospective longitudinal cohort studyAnke Thielebein, Yemisi Ighodalo, Abubakar Taju, et al.
The Lancet. Microbe|May 11, 2022
Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in RwandaJean Claude Semuto Ngabonziza, Tom Decroo, Patrick Migambi, et al.
Pageof 66